Koné-Paut Isabelle
Paediatric Rheumatology, CEREMAI, Bicêtre University Hospital, APHP, Paris SUD, Kremlin bicêtre, France.
Pediatr Rheumatol Online J. 2016 Feb 18;14(1):10. doi: 10.1186/s12969-016-0070-z.
BD is a systemic inflammatory disease with a variable vasculitis. Paediatric onset is very rare and carries a strong genetic component. Oral ulcers and fever of unknown origin are frequent at onset and difficult to distinguish from other inflammatory disorders; therefore, expert opinion is still mandatory to recognize the disease early. An international expert consensus has recently proposed new classification criteria for children with BD. The clinical spectrum of BD is heterogeneous and influenced by gender, ethnicity and country of residence. Young males have the worst prognosis with significantly more frequent neurological, ocular and vascular involvement. BD treatment is aimed at alleviating inflammation. Among all drugs, TNFα inhibitors have become a standard to control severe ocular, neurological and digestive system involvement.
白塞病是一种伴有可变血管炎的全身性炎症性疾病。儿童发病非常罕见,且具有很强的遗传因素。口腔溃疡和不明原因发热在发病时很常见,且难以与其他炎症性疾病区分开来;因此,仍需专家意见以早期识别该疾病。最近,一个国际专家共识提出了白塞病患儿的新分类标准。白塞病的临床谱是异质性的,受性别、种族和居住国家的影响。年轻男性预后最差,神经、眼部和血管受累明显更频繁。白塞病的治疗旨在减轻炎症。在所有药物中,肿瘤坏死因子α抑制剂已成为控制严重眼部、神经和消化系统受累的标准药物。